DR-002 MAP3K1 and MAP2K4 mutations as biomarkers of response to EGFR-based therapy in KRAS wild type colon cancer
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-002 MAP3K1 and MAP2K4 mutations as biomarkers of response to EGFR-based therapy in KRAS wild type colon cancer
In this project, data from CRC patients treated with anti-EGFR therapy will be used to identify biomarkers that predict treatement …
DR-001 Liver-specific mutations in metastatic colorectal cancer
The objective of this project is to determine if the microenvironment of metastases influences mutation patterns. The investigators will test …
DR-035 Learning the subtypes of cancer
Histological, immunohistochemical and gene expression markers are routinely used to stratify tumours into clinically distinct subtypes, some of which have …
DR-034 The forgotten cancer genome – the therapeutic impact of germline
To date, translational cancer genomics has focused on somatic genetics, driven by the desire to identify mutated targets that indicate …
DR-032 ctDNA analysis to predict early recurrence after chemoradiation in head and neck squamous cell cancer (HNSCC)
“Patients with head and neck cancer too advanced for surgical resection have a very poor prognosis, despite the currently standard, …
DR-031 “Genomic characterization of metastatic urothelial carcinoma. DR-031 is an extension of DR-008”
This project aims to unravel molecular mechanisms that drive the high metastatic potential of urothelial cancer.a In addition predictive markers …
DR-029 Genetische biomarkers predictief voor irinotecan respons
Irinotecan is a widely used cytostatic treatment for a broad range of tumor types. However, response is highly variable making …
DR-028 Genomic aberrations ins oft tissue sarcomas / Genomische afwijkingen in weke delen tumoren
This project aims to characterize the genetic landscape of sarcoma tumors and relate this to treatment outcome data. Improving patient …
DR-027 De rol van famacogenetica bij verworven tumorresistentie
The effect of anti-cancer drugs depends on the amount of drug that is present in the tumor cells. If these …
DR-026 The clinical significance of whole genome sequencing data in metastatic breast cancer
This project aims to create a systematic overview of the mutation landscape of metastatic breast cancer patients and identify similarities …
DR-024 Identification of non-coding mutations across cancer types
“Most studies have focused on mutations in the few percent of the genome that encode proteins. In this study, large …
DR-023 Dynamic response assessments to understand responses to immunotherapy in metastatic cancer
The response to checkpoint inhibitors (immunotherapy) is highly variable between tumor types. The researchers will search for novel biomarkers based …
Het aantal WGS- samples dat Hartwig Medical Foundation heeft, is uniek in het onderzoeksveld en groeit snel. Toen we begonnen waren het er 3.500 en dat zijn er nu al meer dan 5.000.